Pulmonary Outcomes on Patients With Lung Fibrosis

July 19, 2025 updated by: Shymaa yussuf abo zaid, South Valley University
The pulmonary fibrosis is lung disease that occurs when lung tissue become damaged and scarred. The objectives of treatment are to improve symptoms and quality of life, and slow disease progression.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

This study will include 60 patients with pulmonary fibrosis from both gender who are aged from 35 - 55 years old.This study will be randomized controlled trial.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Qina, Egypt
        • South Valley University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • both gender.
  • patients with cystic fibrosis.

Exclusion Criteria:

  • severe chronic disorders.
  • heart failure
  • respiratory failure.
  • age less than 35 or older than 55 years old.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Control group
This group will recieve only routine medical care.
Other: Routine medical care
Routine medical care
Other: Pulmonary rehabilitation group
Pulmonary rehabilitation ( breathing exercises, posture drainage, additive techniques with postural drainage like vibration,shaking and percussion, active cycle of breathing techniques, autogenic drainage) plus routine medical care.
Other: Routine medical care
Routine medical care
Other: Pulmonary rehabilitation
Pulmonary rehabilitation ( breathing exercises, posture drainage, additive techniques with postural drainage like vibration,shaking and percussion, active cycle of breathing techniques, autogenic drainage) plus routine care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
FVC
Time Frame: One month
Forced vital capacity (FVC).
One month
FEV1
Time Frame: One month
Forced expiratory volume in the first second (FEV1)
One month
The FEV1 on FVC
Time Frame: One month.
The ratio between FEV1 and FVC
One month.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

South Valley University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2024

Primary Completion (Estimated)

May 1, 2026

Study Completion (Estimated)

August 1, 2026

Study Registration Dates

First Submitted

June 17, 2025

First Submitted That Met QC Criteria

July 19, 2025

First Posted (Actual)

July 28, 2025

Study Record Updates

Last Update Posted (Actual)

July 28, 2025

Last Update Submitted That Met QC Criteria

July 19, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • P.T_INT_11/2024_554

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

I will not share it outside the primary research group.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Fibrosis

Clinical Trials on Routine medical care

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe